stoxline Quote Chart Rank Option Currency Glossary
Kymera Therapeutics, Inc. (KYMR)
23  -0.68 (-2.87%)    12-08 16:00
Open: 23.55
High: 25.19
Volume: 1,788,910
Pre. Close: 23.68
Low: 22.801
Market Cap: 1,276(M)
Technical analysis
2023-12-08 4:44:26 PM
Short term     
Mid term     
Targets 6-month :  29.42 1-year :  34.36
Resists First :  25.19 Second :  29.42
Pivot price 20.7
Supports First :  17.18 Second :  12.22
MAs MA(5) :  22.13 MA(20) :  19.67
MA(100) :  17.71 MA(250) :  24.77
MACD MACD :  1.9 Signal :  1.7
%K %D K(14,3) :  84.6 D(3) :  85.4
RSI RSI(14): 69.2
52-week High :  39.84 Low :  9.6
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ KYMR ] has closed below upper band by 5.7%. Bollinger Bands are 13.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 25.22 - 25.35 25.35 - 25.47
Low: 22.51 - 22.65 22.65 - 22.77
Close: 22.77 - 23.01 23.01 - 23.21
Company Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Headline News

Fri, 08 Dec 2023
Is Kymera Therapeutics Inc (KYMR) Stock a Bad Value Friday? - InvestorsObserver

Fri, 08 Dec 2023
Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474 - Yahoo Finance

Thu, 07 Dec 2023
Is Kymera Therapeutics Inc (KYMR) Stock About to Get Hot Thursday? - InvestorsObserver

Wed, 06 Dec 2023
Should Biotechnology Stock Kymera Therapeutics Inc (KYMR) Be in Your Portfolio Wednesday? - InvestorsObserver

Tue, 07 Nov 2023
BIOTECHNOLOGY VALUE FUND L P Adds to Its Stake in Kymera Therapeutics Inc - Yahoo Finance

Mon, 06 Nov 2023
We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 55 (M)
Held by Insiders 3.446e+007 (%)
Held by Institutions 1.4 (%)
Shares Short 7,320 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.8256e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 216.3 %
Return on Equity (ttm) -19.4 %
Qtrly Rev. Growth 4.685e+007 %
Gross Profit (p.s.) -30.43
Sales Per Share -22.22
EBITDA (p.s.) -7.07349e+007
Qtrly Earnings Growth -2.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -150 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio -4.4
Price to Book value 0
Price to Sales -1.04
Price to Cash Flow 5.29
Stock Dividends
Dividend 0
Forward Dividend 7.45e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android